. 2009 Aug;11(5).
doi: 10.2353/jmoldx.2009.090003.

Pharmacogenetics of solid tumors: directed therapy in breast, lung, and colorectal cancer: a paper from the 2008 william beaumont hospital symposium on molecular pathology

Christine L H Snozek 1 Dennis J O'Kane  Alicia Algeciras-Schimnich  
  • PMID: 19644023
  •     81 References
  •     1 citations


Genetic variability in drug-metabolizing enzymes and signaling pathways affects chemotherapy-related toxicity and treatment outcome in cancer. In breast and colorectal cancer, polymorphisms in metabolic enzymes involved in tamoxifen and irinotecan therapies has led the U.S. Food and Drug Administration to address genetic factors relevant to patient consideration of treatment with these compounds. Tamoxifen therapeutic failure in breast cancer has been associated with reduced CYP2D6 activity due to inefficient activation of tamoxifen. Irinotecan toxicity in colorectal cancer is more common in patients with reduced-activity UGT1A alleles, resulting in excessive exposure to the potent SN-38 metabolite. In colorectal and lung cancers, somatic mutations in the epidermal growth factor receptor and downstream signaling molecules have been associated with the therapeutic outcome of epidermal growth factor receptor-directed therapies. This review discusses the current knowledge regarding the utility of single gene-UGT1A1, CYP2D6, EGFR, and KRAS-or multigene analysis, for optimizing breast, colorectal, and lung cancer therapy. Current advances in these areas highlight how pharmacogenetics help personalized decision-making for patient management.

Targeted therapies in gastrointestinal stromal tumors.
Cristina R Antonescu.
Semin Diagn Pathol, 2008 Nov 19; 25(4). PMID: 19013895
Pharmacogenetics in acute lymphoblastic leukemia.
Meyling H Cheok, Nicolas Pottier, Leo Kager, William E Evans.
Semin Hematol, 2008 Dec 23; 46(1). PMID: 19100367    Free PMC article.
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Heather-Jane Au, Christos S Karapetis, +14 authors, Derek J Jonker.
J Clin Oncol, 2009 Mar 11; 27(11). PMID: 19273701
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
William Pao, Theresa Y Wang, +7 authors, Harold E Varmus.
PLoS Med, 2005 Feb 08; 2(1). PMID: 15696205    Free PMC article.
Highly Cited.
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A Eberhard, Bruce E Johnson, +16 authors, Kenneth J Hillan.
J Clin Oncol, 2005 Jul 27; 23(25). PMID: 16043828
Highly Cited.
EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giuseppe Giaccone, Jose Antonio Rodriguez.
Nat Clin Pract Oncol, 2005 Nov 05; 2(11). PMID: 16270096
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
Matthew P Goetz, James M Rae, +10 authors, James N Ingle.
J Clin Oncol, 2005 Dec 20; 23(36). PMID: 16361630
Highly Cited.
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
Janet K Coller, Niels Krebsfaenger, +8 authors, Thomas E Mürdter.
Br J Clin Pharmacol, 2002 Sep 05; 54(2). PMID: 12207635    Free PMC article.
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Hideto Jinno, Toshiko Tanaka-Kagawa, +7 authors, Jun-Ichi Sawada.
Drug Metab Dispos, 2002 Dec 18; 31(1). PMID: 12485959
Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
Vered Stearns, Katherine L Beebe, Malini Iyengar, Eric Dube.
JAMA, 2003 Jun 05; 289(21). PMID: 12783913
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Jeffrey Cummings, Brian T Ethell, +5 authors, Duncan I Jodrell.
Cancer Res, 2003 Dec 18; 63(23). PMID: 14679008
Irinotecan pharmacogenetics: is it time to intervene?
Howard L McLeod, James W Watters.
J Clin Oncol, 2004 Mar 10; 22(8). PMID: 15007084
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
Federico Innocenti, Samir D Undevia, +9 authors, Mark J Ratain.
J Clin Oncol, 2004 Mar 10; 22(8). PMID: 15007088
Highly Cited.
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Michael D Johnson, Hong Zuo, +6 authors, Todd C Skaar.
Breast Cancer Res Treat, 2004 Apr 28; 85(2). PMID: 15111773
Highly Cited.
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Luca Paoluzzi, Arun S Singh, +5 authors, Alex Sparreboom.
J Clin Pharmacol, 2004 Aug 03; 44(8). PMID: 15286088
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
Zeruesenay Desta, Bryan A Ward, Nadia V Soukhova, David A Flockhart.
J Pharmacol Exp Ther, 2004 May 26; 310(3). PMID: 15159443
Highly Cited.
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
V C Jordan, M M Collins, L Rowsby, G Prestwich.
J Endocrinol, 1977 Nov 01; 75(2). PMID: 591813
Highly Cited.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
Astrid Lièvre, Jean-Baptiste Bachet, +16 authors, Pierre Laurent-Puig.
J Clin Oncol, 2008 Jan 19; 26(3). PMID: 18202412
Highly Cited.
Pharmacogenomics of acute leukemia.
Marc Ansari, Maja Krajinovic.
Pharmacogenomics, 2008 Feb 05; 8(7). PMID: 18240908
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
Kimie Sai, Yoshiro Saito, +9 authors, Teruhiko Yoshida.
Cancer Lett, 2007 Dec 18; 261(2). PMID: 18082937
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
W De Roock, H Piessevaux, +9 authors, S Tejpar.
Ann Oncol, 2007 Nov 14; 19(3). PMID: 17998284
Highly Cited.
Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Tim O Lankisch, Christoph Schulz, +4 authors, Christian P Strassburg.
Cancer Epidemiol Biomarkers Prev, 2008 Mar 20; 17(3). PMID: 18349289
Present treatment and future expectations in advanced pancreatic cancer.
George P Stathopoulos, Nikos Androulakis, +2 authors, Vassilis Georgoulias.
Anticancer Res, 2008 May 29; 28(2B). PMID: 18505070
A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
Anthony Gonçalves, Séverine Esteyries, +13 authors, Frédéric Viret.
BMC Cancer, 2008 Jun 12; 8. PMID: 18544172    Free PMC article.
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
F Cappuzzo, M Varella-Garcia, +14 authors, P A Jänne.
Br J Cancer, 2008 Jun 26; 99(1). PMID: 18577988    Free PMC article.
Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy.
C Braconi, R Bracci, R Cellerino.
Curr Cancer Drug Targets, 2008 Aug 12; 8(5). PMID: 18690842
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.
John F de Groot, Wai Kwan Alfred Yung.
Cancer J, 2008 Oct 07; 14(5). PMID: 18836331
Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
International Breast Cancer Study Group, Marco Colleoni, +6 authors, Richard D Gelber.
J Clin Oncol, 2006 Mar 01; 24(9). PMID: 16505417
Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population.
M Garcia-Barceló, L Y Chow, +4 authors, M M Waye.
Clin Chem, 2000 Jan 06; 46(1). PMID: 10620567
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Nobumitsu Hanioka, Shogo Ozawa, +4 authors, Jun-ichi Sawada Ji.
Drug Metab Dispos, 2002 Mar 20; 30(4). PMID: 11901092
Genetic polymorphisms of the UDP-glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer patients.
Maki Ando, Yuichi Ando, +3 authors, Yoshinori Hasegawa.
Jpn J Cancer Res, 2002 May 31; 93(5). PMID: 12036456    Free PMC article.
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen.
H Kim Crewe, Lisa M Notley, +2 authors, Elizabeth M J Gillam.
Drug Metab Dispos, 2002 Jul 19; 30(8). PMID: 12124303
Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
Jean-François Gagné, Valerie Montminy, +3 authors, Chantal Guillemette.
Mol Pharmacol, 2002 Aug 16; 62(3). PMID: 12181437
KRAS mutations predict response to EGFR inhibitors.
Mitch Raponi, Hans Winkler, Nicholas C Dracopoli.
Curr Opin Pharmacol, 2008 Jul 16; 8(4). PMID: 18619559
Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues.
J L Borgna, H Rochefort.
J Biol Chem, 1981 Jan 25; 256(2). PMID: 7451477
Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
E Coezy, J L Borgna, H Rochefort.
Cancer Res, 1982 Jan 01; 42(1). PMID: 7053859
Highly Cited.
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen.
D W Robertson, J A Katzenellenbogen, +2 authors, B S Katzenellenbogen.
J Steroid Biochem, 1982 Jan 01; 16(1). PMID: 7062732
Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
E A Lien, E Solheim, +3 authors, P M Ueland.
Cancer Res, 1989 Apr 15; 49(8). PMID: 2702659
Highly Cited.
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B Fisher, J P Costantino, +12 authors, N Wolmark.
J Natl Cancer Inst, 1998 Sep 25; 90(18). PMID: 9747868
Highly Cited.
Tamoxifen in the treatment of breast cancer.
C K Osborne.
N Engl J Med, 1998 Nov 26; 339(22). PMID: 9828250
Highly Cited. Review.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Yan Jin, Zeruesenay Desta, +16 authors, David A Flockhart.
J Natl Cancer Inst, 2005 Jan 06; 97(1). PMID: 15632378
Highly Cited.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A Howell, J Cuzick, +8 authors, ATAC Trialists' Group.
Lancet, 2005 Jan 11; 365(9453). PMID: 15639680
Highly Cited.
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Leslie E Carlini, Neal J Meropol, +6 authors, Rebecca L Blanchard.
Clin Cancer Res, 2005 Feb 15; 11(3). PMID: 15709193
Targeted cancer therapies.
Jean-Yves Blay, Axel Le Cesne, Laurent Alberti, Isabelle Ray-Coquart.
Bull Cancer, 2005 Mar 08; 92(2). PMID: 15749638
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Young Chai Lim, Zeruesenay Desta, David A Flockhart, Todd C Skaar.
Cancer Chemother Pharmacol, 2005 Feb 03; 55(5). PMID: 15685451
Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene.
Tim O Lankisch, Arndt Vogel, +5 authors, Christian P Strassburg.
Mol Pharmacol, 2005 Feb 18; 67(5). PMID: 15716465
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
L Wang, R Weinshilboum.
Oncogene, 2006 Mar 22; 25(11). PMID: 16550163
Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer.
S Nagar, R P Remmel.
Oncogene, 2006 Mar 22; 25(11). PMID: 16550166
Irinogenetics: what is the right star?
Federico Innocenti, Everett E Vokes, Mark J Ratain.
J Clin Oncol, 2006 Apr 26; 24(15). PMID: 16636339
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, +19 authors, National Surgical Adjuvant Breast and Bowel Project (NSABP).
JAMA, 2006 Jun 07; 295(23). PMID: 16754727
Highly Cited.
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Silvana Borges, Zeruesenay Desta, +11 authors, David A Flockhart.
Clin Pharmacol Ther, 2006 Jul 04; 80(1). PMID: 16815318
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy.
Peter J O'Dwyer, Robert B Catalano.
J Clin Oncol, 2006 Sep 30; 24(28). PMID: 17008691
Raloxifene and the prevention of breast cancer.
Therese B Bevers.
Expert Opin Pharmacother, 2006 Oct 25; 7(16). PMID: 17059385
TAILORx: trial assigning individualized options for treatment (Rx).
Joseph A Sparano.
Clin Breast Cancer, 2006 Nov 10; 7(4). PMID: 17092406
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas, Arno Floore, +9 authors, Laura J Van't Veer.
BMC Genomics, 2006 Nov 01; 7. PMID: 17074082    Free PMC article.
Highly Cited.
Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
Donna Young.
Am J Health Syst Pharm, 2006 Nov 16; 63(23). PMID: 17105997
Adding pharmacogenetics information to drug labels: lessons learned.
Susanne B Haga, Kenneth E Thummel, Wylie Burke.
Pharmacogenet Genomics, 2006 Nov 17; 16(12). PMID: 17108808
Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Federico Innocenti, Mark J Ratain.
Pharmacogenomics, 2006 Dec 23; 7(8). PMID: 17184208
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
Roshni P Ramchandani, Yaning Wang, +7 authors, Jogarao V S Gobburu.
J Clin Pharmacol, 2006 Dec 29; 47(1). PMID: 17192505
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Matthew P Goetz, Stacey K Knox, +15 authors, James N Ingle.
Breast Cancer Res Treat, 2006 Nov 23; 101(1). PMID: 17115111
Highly Cited.
Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients--a double-blind, randomized study.
S Loibl, K Schwedler, +3 authors, M Kaufmann.
Ann Oncol, 2007 Jan 19; 18(4). PMID: 17229772
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
F Di Fiore, F Blanchard, +13 authors, T Frebourg.
Br J Cancer, 2007 Mar 22; 96(8). PMID: 17375050    Free PMC article.
Highly Cited.
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Erminia Massarelli, Marileila Varella-Garcia, +6 authors, Ignacio I Wistuba.
Clin Cancer Res, 2007 May 17; 13(10). PMID: 17504988
Highly Cited.
Insights, challenges, and future directions in irinogenetics.
Tae Won Kim, Federico Innocenti.
Ther Drug Monit, 2007 May 29; 29(3). PMID: 17529881
UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Clinton F Stewart, John C Panetta, +9 authors, Lisa M McGregor.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577039
UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Yuichi Ando, Ken-Ichi Fujita, Yasutsuna Sasaki, Yoshinori Hasegawa.
Curr Opin Mol Ther, 2007 Jul 05; 9(3). PMID: 17608024
Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
Ken-ichi Fujita, Yuichi Ando, +7 authors, Yasutsuna Sasaki.
Cancer Chemother Pharmacol, 2007 Apr 05; 60(4). PMID: 17406868
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Janelle M Hoskins, Richard M Goldberg, +2 authors, Howard L McLeod.
J Natl Cancer Inst, 2007 Aug 31; 99(17). PMID: 17728214
Highly Cited.
Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study.
Lisa R Bomgaars, Mark Bernstein, +5 authors, Susan M Blaney.
J Clin Oncol, 2007 Oct 11; 25(29). PMID: 17925558
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.
Tetsuya Mitsudomi, Yasushi Yatabe.
Cancer Sci, 2007 Sep 25; 98(12). PMID: 17888036
Highly Cited. Review.
Combining chemotherapy and targeted therapies in metastatic colorectal cancer.
J Rodriguez, R Zarate, +4 authors, I Gil-Bazo.
World J Gastroenterol, 2007 Nov 09; 13(44). PMID: 17990352    Free PMC article.
Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity.
Hugo Girard, Eric Lévesque, +3 authors, Chantal Guillemette.
Pharmacogenet Genomics, 2007 Nov 16; 17(12). PMID: 18004212
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Josep Tabernero, Eric Van Cutsem, +12 authors, Aimery de Gramont.
J Clin Oncol, 2007 Nov 21; 25(33). PMID: 18024868
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
Magnus Ingelman-Sundberg, Sarah C Sim, Alvin Gomez, Cristina Rodriguez-Antona.
Pharmacol Ther, 2007 Nov 16; 116(3). PMID: 18001838
Highly Cited. Review.
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
M P Goetz, A Kamal, M M Ames.
Clin Pharmacol Ther, 2007 Sep 21; 83(1). PMID: 17882159    Free PMC article.
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Peyman Haghighat, Tanios Bekaii-Saab.
J Natl Compr Canc Netw, 2008 Oct 18; 6(9). PMID: 18926099
Clinical and pharmacogenetic factors associated with irinotecan toxicity.
Dinemarie Kweekel, Henk-Jan Guchelaar, Hans Gelderblom.
Cancer Treat Rev, 2008 Jun 19; 34(7). PMID: 18558463
Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Xun Cai, Chuan Tian, +9 authors, Chungang Wang.
Cancer Biol Ther, 2017 Mar 10; 18(3). PMID: 28278081    Free PMC article.